Nanoscan (Human Serum Albumin)

Human serum albumin is the main plasma protein that contributes to oncotic pressure. When given intravenously, it raises the colloid osmotic gradient, drawing water from the interstitial space into the vascular compartment, thereby expanding circulating volume and supporting hemodynamics.

The dose of Nanoscan is individualized by the prescribing clinician based on the patient’s clinical status, degree of volume loss, and target plasma albumin level. The prescriber determines the volume and rate of infusion according to established guidelines.

Safety data for human serum albumin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only considered when the potential benefit justifies any potential risk, and it should be prescribed by a qualified health professional.

To place an order, submit an enquiry on the Nanoscan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and required import documentation.

Compared with synthetic colloids such as hydroxyethyl starch, human serum albumin offers a natural protein that is less associated with coagulopathy and renal dysfunction. However, albumin is more expensive and requires cold‑chain storage, while synthetic options may have different safety profiles.

Nanoscan should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken, and it should remain in its original packaging until use to maintain sterility and potency.

Nanoscan is supplied as a sterile solution for injection and is administered intravenously. The infusion rate is set by the treating physician, often through a controlled infusion pump, and the product may be diluted with compatible IV fluids as directed.

Serious adverse reactions include anaphylaxis, severe hypotension, volume overload leading to pulmonary edema, and rare thrombotic events. Clinicians should monitor patients closely for signs of allergic reaction, respiratory distress, or sudden changes in hemodynamic status.

Nanoscan is contraindicated in patients with known hypersensitivity to human serum albumin or any component of the formulation. Caution is also advised in individuals with severe heart failure, uncontrolled hypertension, or active pulmonary edema where additional volume may be harmful.